Clinical trials: Advanced Gastric Carcinoma
Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction…
- Trial name
- NCT06415669
- Testing
- Paclitaxel for injection (albumin-bound), Adebrelimab, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or…
- Trial name
- NCT07362186
- Testing
- LM-108 in combination with Toripalimab, Paclitaxel injection intravenous infusion
- Where
- China
- Volunteers
- 400 people
- Sponsor
- LaNova Medicines Limited
Colorectal Carcinoma, Gastric Carcinoma
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread.
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06882746
- Testing
- BI 765049
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Gastric Cancer, Chemotherapy Effect
Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study which will enroll 524 patients in total. Patients with eligibility will be registered, pre-enrolled and receive three cycles of SOX.
- Trial name
- RESONANCE-II (NCT04483076)
- Testing
- Chemotherapy drug, Gastrectomy, Laparoscopic exploration
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Chinese PLA General Hospital
Cancer of Stomach
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial
The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.
- Trial name
- NCT00164892
- Testing
- Oral Vioxx (Rofecoxib)
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Chinese University of Hong Kong
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Gastric Cancer, MSI-H
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a…
- Conditions
- Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer
- Trial name
- CIME (NCT06346197)
- Testing
- Balstilimab, Botensilimab, Folfox Protocol
- Where
- 7 sites in France
- Volunteers
- 132 people
- Sponsor
- Centre Leon Berard
Gastric Cancer
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
The purpose of this study is to evaluate the clinical efficacy and safety of HLX22 in the HER2+ Locally Adanved or Metastatic Gastric Cancer as the first-line therapy.This study consists of three periods, screening period (28…
- Trial name
- NCT04908813
- Testing
- HLX22, Trastuzumab, Oxaliplatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Henlius Biotech
Gastric Cancer, Colorectal Cancer
A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and…
- Trial name
- NCT04513223
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Gastric Cancer
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis.
- Trial name
- NCT07486310
- Testing
- Doxorubicin (Adriamycin), VRT106
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Gastric Cancer (GC)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.
This study is a multicenter, open-label, dose-escalation, PK expansion, and cohort expansion, first-in-human phase I/II study to evaluate the safety, tolerability, PK profile, and preliminary antitumor efficacy of SYS6062, a…
- Conditions
- Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07897227
- Testing
- SYS6062
- Volunteers
- 260 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Cervical Cancer
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)
This is a single center phase 1 trail to observe safety and efficacy of metronomic capecitabine plus PD-L1 antibody camrelizumab as third-line regimen to treat HER2 negative advanced gastric cancer patients.
- Trial name
- NCT04508686
- Testing
- Capecitabine, camrelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Gastric Cancer, Total Gastrectomy
Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial
The goal of this clinical trial is to compare the effectiveness of enhanced follow-up with standard follow-up in postoperative patients with advanced gastric cancer who have undergone radical gastrectomy.
- Conditions
- Gastric Cancer, Total Gastrectomy, Postoperative Care, Quality of Life
- Trial name
- NCT06468969
- Testing
- Enhanced Follow-up
- Volunteers
- 158 people
- Sponsor
- Fudan University
Gastrointestinal Cancer, Colorectal Cancer
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
- Conditions
- Gastrointestinal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer
- Trial name
- NCT04077372
- Testing
- Serious Illness Conversation Guide (SICG), Quality of Life (QOL) survey
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Gastric Cancer, Esophageal Cancer
Perception Prognosis, Goals of Treatment, and Communication
The purpose of this research study is to assess what the participant understands about their illness, prognosis, the goals of the cancer treatment and their communication with their oncology providers.
- Conditions
- Gastric Cancer, Esophageal Cancer, Pancreatic Cancer, Liver Cancer
- Trial name
- NCT01401894
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)
A IIT Study of 177Lu-DOTA-SNA040
This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced…
- Conditions
- Advanced Solid Tumors (Such as Gastric Cancer), Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction), Advanced Solid Tumors (Such as Pancreatic Cancer), Advanced Solid Tumors (Such as Cholangiocarcinoma)
- Trial name
- NCT07595237
- Testing
- 177Lu-DOTA-SNA040
- Where
- China
- Volunteers
- 12 people
- Sponsor
- SmartNuclide Biopharma
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation
- Trial name
- NCT06560645
- Testing
- PRT7732
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 42 people
- Sponsor
- Prelude Therapeutics Incorporated
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or…
- Trial name
- NCT06271837
- Testing
- Trastuzumab deruxtecan, Bevacizumab
- Where
- 29 sites in China
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene